DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/kjcttc/otitis_media) has announced the addition of the "Otitis Media - Pipeline Review, H2 2015" report to their offering.
This report provides comprehensive information on the therapeutic development for Otitis Media, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Otitis Media and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Companies Involved in Therapeutics Development
- Cellceutix Corporation
- ContraFect Corporation
- GlaxoSmithKline Plc
- Laboratorios SALVAT S.A.
- Merck & Co., Inc.
- MerLion Pharmaceuticals Pte Ltd
- Oticpharma Ltd
- Otonomy, Inc.
- Yuhan Corporation
- (fluocinolone acetonide + ciprofloxacin hydrochloride)
- betahistine hydrochloride
- brilacidin tetrahydrochloride
- ciprofloxacin hydrochloride SR
- ciprofloxacin SR
- Recombinant Peptide to Inhibit DNA for Otitis Media and Haemophilus Influenzae Infections
For more information visit http://www.researchandmarkets.com/research/kjcttc/otitis_media